Immunotherapy in the Age of Vaccinomics

Vaccinomics – The matching of individual immune response genetics to specific target peptides in vaccines. Designs for success. The field of immunology and vaccine design has reached a new paradigm of understanding as to how vaccines work, or don’t work, based on our understanding of immune response genetics. In principle the genetic variables, or ‘alleles’…

Details

Presentation of HER2/neu Vaccine Development Program at Third Annual Cancer Vaccines and Active Immunity Summit, Boston, June 27-29, 2012

June 25, 2012, Seattle, WA, TapImmune Inc (OTCBB: TPIV) has announced it will present a poster at the Third Annual Cancer Vaccines and Active Immunotherapy Summit in Boston describing it’s Her-2/Neu vaccine development program. This will include scientific details describing and differentiating this vaccine program from others in clinical development. The prime and boost approach…

Details

TapImmune Licenses HER2/neu Antigen Technology from Mayo Clinic for Incorporation into a Vaccine to Treat HER2/neu Breast Cancer.

Addition of Class I antigen provides new advance in development of HER2/neu vaccines. April 16, 2012, Seattle WA, TapImmune Inc. (OTCBB: TPIV) has announced that it has signed an Exclusive Agreement with the Mayo Foundation for Education & Research, Rochester, MN, to License a proprietary MHC Class I HER2/neu antigen technology. This antigen was discovered…

Details